Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR142 | Q7Z601 | 3/20 | 0.51 |
| ▸ | NOX1 | Q9Y5S8 | 11/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2685860 | 0.85 | GPR142 (0.62) | GPR142NOX1KDM4EALDH1A1HPGD | |
| SCHEMBL2685524 | 0.82 | GPR142 (0.50) | GPR142NOX1KDM4EALDH1A1HPGD | |
| SCHEMBL2687848 | 0.80 | GPR142 (0.71) | GPR142NOX1 | |
| SCHEMBL2687851 | 0.80 | GPR142 (0.71) | GPR142NOX1 | |
| SCHEMBL2686192 | 0.77 | NOX1 (0.55) | GPR142NOX1KDM4EALDH1A1HPGD | |
| SCHEMBL2685412 | 0.75 | GPR142 (0.51) | GPR142NOX1KDM4EALDH1A1HPGD | |
| SCHEMBL2685334 | 0.74 | GPR142 (0.60) | GPR142NOX1KDM4EALDH1A1HPGD | |
| SCHEMBL2685328 | 0.74 | GPR142 (0.60) | GPR142NOX1KDM4EALDH1A1HPGD | |
| SCHEMBL2684254 | 0.73 | GPR142 (0.67) | GPR142NOX1KDM4EALDH1A1HPGD | |
| SCHEMBL2685591 | 0.71 | GPR142 (0.57) | GPR142NOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785468-B2 | Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions | AMGEN INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20120115811-A1 | PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS | AMGEN INC. (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115811-A1 | PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS | IAPP, INSR, AMY2A | GPR142 2779/4885NOX1 2943/4885KDM4E 3283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.